To provide a sulfatase inhibitor which needs a compound limiting or preventing the usage of estrogen in hormone-dependent tumor, and does not have an estrogenic active component.

The invention relates to a new estratriene expressed by general formula (I) which contains several sulfamoyloxy groups per molecule (m=1-5). They are produced by reacting an appropriate steroid alcohol with sulfamoyl chloride or n-alkyl chloride or alkanoylsulfamoyl chloride in the presence of a buffer or a base. The compounds of formula (I) are characterized by high sulfatase activity and are therefore suitable for the treatment of diseases responding to sulfatase inhibition. The high target specificity of the inventive compounds in relation to sulfatase and estrogen transcription assays enable the compounds, which are provided with a radiolabel e.g. [18F] fluorine instead of F, to be used as potential markers in tumor diagnosis.